CHIMU Okinawa Study
- Conditions
- coronary heart disease
- Registration Number
- JPRN-jRCTs071180054
- Lead Sponsor
- iwabuchi Masashi
- Brief Summary
Clopidogrel is reported to be less effective in the CYP2C19 gene polymorphism in the middle active type and the low active type, and in particular, about 20% is said to be equivalent to that in Asians. In this study, it was found that clopidogrel has the same platelet-suppressing effect as prasugrel in highly active patients without mutations in the CYP2C19 gene polymorphism. Therefore, if it is found that there is no mutation in the CYP2C19 gene polymorphism, the use of inexpensive clopidogrel can be consi
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 166
Patients who have chronic coronary artery disease patients who are taking aspirin and clopidogrel for more than 1 month and satisfy the following items
(1) Patients whose age at agreement acquisition is 20 years old or over and under 85 years old and whose body weight is 50 kg or more
(2) Patients who gave adequate explanation on the participation of this study and gained written consent
1)Dialysis
2)Dangerously ill liver disease patient
3)Malignant tumor of the activity
4)The patient that art of planned coronary revasculalization is not completed
5)PCI enforcement patients within 7 days
6)Dangerously ill heart failure patient(LVEFless than 30%. NYHA IV)
7)More than less than 50,000 number of the platelets /micro l or 500,000 /micro l, it is less than 30% of hematocrit or more than 50%
8)Bleeding patient
9)Patients who need treatment with anticoagulant
10)The patient who is participating in other clinical trials
11)Pregnant patient
12)the patient who judged that the medical attendant was inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method